The Cure Starts Now has funded $21,188,327 in pediatric brain cancer research in partnership with the DIPG / DMG Collaborative. This includes 132 grants at over 100 hospitals in 17 countries.




University of Queensland Diamantina Institute – $100,000

Amount
$100,000.00
Date
November 2022

Innovative Models of the Brain Microenvironment to Identify New Treatments for Medulloblastoma

Erasmus University Medical Center – $432,354

Amount
$432,354.00
Date
November 2022

Development and optimization of targeted radiopharmaceutical therapies for pediatric brain tumors; a world-first translational study. Acronym: TARGET-FIRST

Cincinnati Children's Hospital Medical Center – $60,000

Amount
$60,000.00
Date
November 2022

Targeting Histone Lysine Demethylases to Treat Diffuse Intrinsic Pontine Glioma

Cincinnati Children's Hospital Medical Center – $153,867

Amount
$153,867.00
Date
November 2022

Combining innovative proton radiotherapy with targeted and immune therapies to treat DMG/DIPG

Hunter Medical Research Institute – $232,932

Amount
$232,932.00
Date
November 2022

Enhancing the recruitment of tumor infiltrating lymphocytes to improve responses to DMG therapies

SONALASENSE – $198,436

Amount
$198,436.00
Date
November 2022

A Phase 1/2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2 in Patients With DIPG

UPMC Childrens Hospital of Pittsburgh – $100,000

Amount
$100,000.00
Date
November 2022

The Role of QPRT and NAD Pathways in DIPG Treatment Resistance (Continued)

Ann and Robert H. Lurie Children's Hospital of Chicago – $100,000

Amount
$100,000.00
Date
November 2022

Intranasal Delivery of Targeting Nanotherapeutics for DIPG

The Hospital For Sick Children (SickKids) – $100,000

Amount
$100,000.00
Date
November 2022

Synthetic lethality screening with methionine restriction for treatment of DIPG

University of Texas MD Anderson Cancer Center – $100,000

Amount
$100,000.00
Date
November 2022

Viroimmunotherapy for pediatric brain tumors

Hunter Medical Research Institute – $200,000

Amount
$200,000.00
Date
November 2022

DMG COMBATT 2.0: Diffuse Midline Glioma COMbined Anti-Tumor Targeting 2.0

The Institute of Cancer Research – $501,183

Amount
$501,183.00
Date
November 2022

Translating Mechanism to Patient Benefit for ACVR1-Mutant Diffuse Intrinsic Pontine Glioma (DIPG)

Children’s Hospital of Philadelphia – $12,500

Amount
$12,500.00
Date
August 2022

Understanding the influence of the microbiome on treatment and outcome of pediatric high-grade central nervous system tumors

Cincinnati Children's Hospital – $50,000

Amount
$50,000.00
Date
May 2022

Targeting Histone Lysine Demethylases to Treat Diffuse Intrinsic Pontine Glioma

SIOPe DIPG/DMG Registry – $779,018

Amount
$779,018.00
Date
March 2022

Renewal of the European DIPG/DMG Registry